Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Macrophages are induced by LPS to release a number of products that determine the host response during gram negative sepsis. To examine the role of one such substance, tumor necrosis factor (TNF), in mediating LPS-induced injury, we employed a rabbit model of endotoxic shock to (a) determine the kinetics and extent of release of TNF into plasma after injection of LPS, and (b) to evaluate the protective effect of in vivo neutralization of LPS-induced TNF by prior infusion of anti-TNF antibody. TNF was maximally induced 45-100 min after injection of 10 micrograms i.v. parent Salmonella minnesota Re595 LPS or 250 micrograms Re595 LPS-HDL complexes. Maximal induction of TNF by LPS was associated with development of hypotension, focal hepatic necrosis, intravascular fibrin deposition and lethality. Based on (a) the peak levels of TNF observed in serum, 2.5 X 10(3) U/ml, (b) the specific activity of purified rabbit macrophage-derived TNF, 1 X 10(8) U/mg, and (c) the biphasic disappearance of intravenously injected purified TNF (t1/2 = 0.5 min, 11 min) we constructed a kinetic model showing that at least 130 micrograms of TNF (1.3 X 10(7) U) was released into plasma 30-200 min postinjection of LPS. Prior infusion of anti-TNF antibody (30-45 min before LPS injection) resulted in neutralization of the LPS-induced serum TNF activity and provided significant protection from the development of hypotension, fibrin deposition, and lethality. Thus, these results provide further evidence that TNF plays a central role mediating the pathophysiologic changes that occur during gram negative endotoxic shock.

[1]  W. Fiers,et al.  TUMOR NECROSIS FACTOR INCREASES THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN ENDOTHELIAL CELLS IN VITRO AND IN RATS IN VIVO , 1988, Thrombosis and Haemostasis.

[2]  B. Beutler,et al.  CACHECTIN: MORE THAN A TUMOR NECROSIS FACTOR , 1988 .

[3]  J. Adamson,et al.  Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells. , 1987, Journal of immunology.

[4]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[5]  D. Remick,et al.  Acute in vivo effects of human recombinant tumor necrosis factor. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[6]  W. Fiers,et al.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[8]  J. D. Albert,et al.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.

[9]  B. Aggarwal,et al.  Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor‐Alpha , 1987, Journal of leukocyte biology.

[10]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[11]  A. Asher,et al.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.

[12]  Y. Kobayashi,et al.  Production of lymphotoxin and tumour necrosis factor by a T-cell hybridoma. , 1987, Immunology.

[13]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.

[14]  R. Pain,et al.  Tumour necrosis factor is a compact trimer , 1987, FEBS letters.

[15]  D. Loskutoff,et al.  INTERLEUKIN 1 (IL-1) AND TUMOR NECROSIS FACTOR (TNF) ACTIVATION OF VASCULAR ENDOTHELIUM: EFFECTS ON PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) AND TISSUE-TYPE PLASMINOGEN ACTIVATOR (tPA) , 1987, Thrombosis and Haemostasis.

[16]  A. Waage,et al.  Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients , 1986, Scandinavian journal of immunology.

[17]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[18]  L. Old,et al.  Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor , 1986, The Journal of experimental medicine.

[19]  R. Philip,et al.  Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1 , 1986, Nature.

[20]  R. Ulevitch,et al.  Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum , 1986, The Journal of experimental medicine.

[21]  G. Weissmann,et al.  Tumor necrosis factor provokes superoxide anion generation from neutrophils. , 1986, Biochemical and biophysical research communications.

[22]  H. Ochs,et al.  An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. , 1986, Journal of immunology.

[23]  J. Gamble,et al.  Stimulation of neutrophils by tumor necrosis factor. , 1986, Journal of immunology.

[24]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[26]  L. Chess,et al.  Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 , 1986, The Journal of experimental medicine.

[27]  J. Larrick,et al.  Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. , 1986, Biochemical and biophysical research communications.

[28]  S. Kuroda,et al.  Molecular cloning and expression in Escherichia coli of the cDNA coding for rabbit tumor necrosis factor. , 1986, DNA.

[29]  W. Fiers,et al.  Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. , 1986, The American journal of pathology.

[30]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.

[31]  C. Galanos,et al.  Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin , 1986, Infection and immunity.

[32]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[33]  J. D. Albert,et al.  Cachectin/tumor necrosis factor participates in reduction of skeletal muscle membrane potential: Evidence for bioactivity in plasma during critical illness , 1986 .

[34]  Flick Da,et al.  Pharmacokinetics of murine tumor necrosis factor. , 1986 .

[35]  D. A. Flick,et al.  Pharmacokinetics of murine tumor necrosis factor. , 1986, Journal of immunopharmacology.

[36]  J. Gamble,et al.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Aggarwal,et al.  Human interleukin 1 is a cytocidal factor for several tumor cell lines. , 1985, Journal of immunology.

[38]  B. Beutler,et al.  Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. , 1985, Journal of immunology.

[39]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[40]  A. Sakurai,et al.  PURIFICATION AND PARTIAL AMINO ACID SEQUENCE OF RABBIT TUMOR NECROSIS FACTOR , 1985, International journal of cancer.

[41]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[42]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[43]  B. Beutler,et al.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells , 1985, The Journal of experimental medicine.

[44]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[45]  J. Quesada,et al.  Pharmacokinetic study of partially pure gamma-interferon in cancer patients. , 1984, Cancer research.

[46]  J A Koziol,et al.  VARCOV: a computer program for the distribution-free analysis of growth and response curves. , 1984, Computer programs in biomedicine.

[47]  R. Ulevitch,et al.  Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). , 1983, Journal of immunology.

[48]  J. Oppenheim,et al.  Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1. , 1983, Journal of immunology.

[49]  G. Gifford,et al.  In vitro production of rabbit macrophage tumor cell cytotoxin , 1983, International journal of cancer.

[50]  S. Rosenberg,et al.  The fate of interleukin-2 after in vivo administration. , 1983, Journal of immunology.

[51]  J. Lipton,et al.  Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. , 1982, The Journal of clinical investigation.

[52]  R. Munford,et al.  Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. , 1981, The Journal of clinical investigation.

[53]  T. Boulikas,et al.  Silver staining of proteins in polyacrylamide gels. , 1981, Analytical biochemistry.

[54]  R. Ulevitch,et al.  In vivo interaction of bacterial lipopolysaccharide (LPS) with rabbit platelets: modulation by C3 and high density lipoproteins. , 1981, Journal of immunology.

[55]  G. Gifford,et al.  Purification and physico-chemical characterization of rabbit tumor necrosis factor. , 1980, Journal of immunology.

[56]  C. Galanos,et al.  Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. , 1980, Infection and immunity.

[57]  R. Ulevitch,et al.  The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. , 1979, Journal of immunology.

[58]  R. Ulevitch,et al.  New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. , 1979, The Journal of clinical investigation.

[59]  R. Ulevitch,et al.  The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. , 1978, The Journal of clinical investigation.

[60]  R. Ulevitch,et al.  The effects of bacterial endotoxins on host mediation systems. A review. , 1978, The American journal of pathology.

[61]  R. Ulevitch,et al.  The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey. , 1978, The American journal of pathology.

[62]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[63]  R. Ulevitch,et al.  Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes , 1978, Infection and immunity.

[64]  D. Rosenstreich,et al.  Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo , 1976, Infection and immunity.

[65]  R. Ulevitch,et al.  Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement , 1975, The Journal of experimental medicine.

[66]  O. Westphal Bacterial Endotoxins (Part 2 of 2) , 1975 .

[67]  C. Shipman Trypsin: A. Mammalian Tissues , 1973 .

[68]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[69]  C. Galanos,et al.  A new method for the extraction of R lipopolysaccharides. , 1969, European journal of biochemistry.

[70]  R. Aster,et al.  PLATELET SEQUESTRATION IN MAN. I. METHODS. , 1964, The Journal of clinical investigation.

[71]  G. Ashwell,et al.  Estimation of 3-Deoxy Sugars by Means of the Malonaldehyde–Thiobarbituric Acid Reaction , 1960, Nature.